Male androgenetic alopecia

Hoffmann, Rolf

doi:10.1046/j.1365-2230.2002.01086.x

Cited by 55 publications

(44 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the pathogenesis, it requires an adequate presence of androgens and a genetic predisposition. In the balding scalp, a miniaturization of genetically programmed hair follicles is driven by an increased uptake, metabolism and conversion of testosterone to dihydrotestosterone (DHT) by 5α-reductase [2, 3]. In men with AGA, hair loss occurs in the frontotemporal and vertex regions of the scalp.…”

Section: Introductionmentioning

confidence: 99%

An Open, Randomized, Comparative Study of Oral Finasteride and 5% Topical Minoxidil in Male Androgenetic Alopecia

Arca¹,

Açıkgöz²,

Taştan³

et al. 2004

Dermatology

View full text Add to dashboard Cite

Background and Aim: Androgenetic alopecia (AGA) is undoubtedly the most common form of hair loss in males. It is a condition which may cause cosmetic and psychosocial problems in androgen-dependent cases. In this open, randomized and comparative study we evaluated the efficacy of oral finasteride and 5% topical minoxidil treatment for 12 months in 65 male patients with mild to severe AGA. Methods: We randomly assigned 40 (61.53%) patients to receive 1 mg/day oral finasteride for 12 months, and 25 (38.47%) patients applied 5% topical minoxidil solution twice daily for 12 months. Results: There were no significant differences between the 2 groups considering age, age of onset of hair loss, family history and type of hair loss (p > 0.05). In the clinical evaluation at the endpoint of treatment, the clinical cure rates (i.e. increased intensity of hair) were 80% (32/40) for the oral finasteride group and 52% (13/25) for the 5% topical minoxidil group. Encountered side effects were all mild, and there was no need to stop the treatment. In the group given oral finasteride, side effects were noted in 7 patients: 6 patients suffered from loss of libido, and 1 patient had an increase in other body hairs; irritation of the scalp was seen in 1 patient in the group administered 5% minoxidil. These adverse events disappeared as soon as the treatment was stopped. The laboratory data on both drug groups did not show any statistically or clinically significant intragroup changes from baseline values to the endpoint (p > 0.05), except the level of serum total testosterone which was increased, and free testosterone and serum prostate-specific antigen in the finasteride group which were statistically decreased from baseline values to the endpoint (p < 0.05). Conclusion: In this comparative study of systemic finasteride and topical minoxidil, it was concluded that both drugs were effective and safe in the treatment of mild to severe AGA, although oral finasteride treatment was more effective (p < 0.05). Adverse events were not considered important either, and these side effects disappeared as soon as the treatment was stopped.

show abstract

Section: Introductionmentioning

confidence: 99%

An Open, Randomized, Comparative Study of Oral Finasteride and 5% Topical Minoxidil in Male Androgenetic Alopecia

Arca¹,

Açıkgöz²,

Taştan³

et al. 2004

Dermatology

View full text Add to dashboard Cite

show abstract

“…2 Lower prevalence has been seen among Asian, Native American, and African American men, whereas high prevalence has been found among men of white race/ethnicity. 3 The changes of AGA are androgen dependent and follow an inheritance mode with gene polymorphisms. 3 To our knowledge, only 1 gene that encodes the androgen receptor has been identified.…”

mentioning

confidence: 99%

“…3 The changes of AGA are androgen dependent and follow an inheritance mode with gene polymorphisms. 3 To our knowledge, only 1 gene that encodes the androgen receptor has been identified. 4 While prerequisites are androgens and a genetic predisposition, clinical practice has shown that simply blocking androgens does not result in the conversion of miniaturized follicles to terminal ones in advanced alopecia.…”

mentioning

confidence: 99%

Association of Androgenetic Alopecia With Smoking and Its Prevalence Among Asian Men

Chen²

2007

Arch Dermatol

104

View full text Add to dashboard Cite

“…Other known and validated factors influencing the development of common baldness are few but include polygenic inheritance patterning, higher levels of 5-alpha reductase, which is responsible for converting testosterone into a more potent androgen, and aging (Hamilton, 1951;Hoffman, 2002;Price, 2003;Severi et al, 2003;). Many women with alopecia, however, have normal levels of circulating androgens.…”

Section: Discussionmentioning

confidence: 99%

Premature Graying, Balding, and Low Bone Mineral Density in Older Women and Men

et al. 2007

View full text Add to dashboard Cite

Objectives-Studies of balding and premature graying in association with bone mineral density (BMD) have yielded inconsistent results. We report the association of balding or graying with BMD in older adults.Methods-BMD was measured at the spine, hip, and total body in 1,207 subjects. Of these, 508 women and 380 men responded to a 1986 survey about balding patterns; in 1994 all subjects answered questions about graying.Results-Among men, 10.7% reported graying, and 51.1%, balding; 9.9% of women reported graying, and 9.5%, balding. Models were adjusted for age, body mass index, alcohol consumption, smoking, exercise, calcium supplements, diuretics, glucocorticoids, thyroid hormone, and estrogen. Graying was not significantly associated with BMD in men or women. Balding men averaged 5% lower total body BMD (p ≤ 0.05), and balding women had ˜24% higher mean hip BMD (p ≤ 0.05). Graying and balding women reported a higher proportion of current estrogen use; balding women reported more use of glucocorticosteroids. Balding women currently using estrogen may explain the higher BMD.Conclusions-Premature graying was not associated with BMD in women or men. Balding women had significantly higher hip BMD which may have been partially attributable to estrogen use, and non-balding men had significantly higher total body BMD.

show abstract

Male androgenetic alopecia

Cited by 55 publications

References 48 publications

An Open, Randomized, Comparative Study of Oral Finasteride and 5% Topical Minoxidil in Male Androgenetic Alopecia

An Open, Randomized, Comparative Study of Oral Finasteride and 5% Topical Minoxidil in Male Androgenetic Alopecia

Association of Androgenetic Alopecia With Smoking and Its Prevalence Among Asian Men

Premature Graying, Balding, and Low Bone Mineral Density in Older Women and Men

Contact Info

Product

Resources

About